Effects of Chronic Treatment with a Type 5 Phosphodiesterase Inhibitor on Erectile Function in Diabetic Rats.
- Author:
Min Chul CHO
1
;
Kwanjin PARK
;
Jae Seung PAICK
Author Information
1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea. jspaick@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Rat;
Diabetes;
Erectile dysfunction;
Phosphodiesterase inhibitor
- MeSH:
Animals;
Apoptosis;
Arterial Pressure;
Erectile Dysfunction;
Hyperglycemia;
Injections, Intraperitoneal;
Male;
Models, Animal;
Muscle, Smooth;
Rats*;
Rats, Sprague-Dawley;
Streptozocin
- From:Korean Journal of Andrology
2007;25(3):129-134
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We investigated whether chronic treatment with a type 5 phosphodiesterase inhibitor (PDE5I) could suppress corporal apoptosis and improve erectile function in diabetic erectile dysfunction. MATERIALS AND METHODS: Sprague-Dawley rats (12 weeks old) were assigned into 1) normal control 2) diabetes, and 3) diabetes with PDE5I treatment groups (n=12 per group). After inducing diabetes with intraperitoneal injection of streptozotocin, the diabetic and PDE5I-treatment groups were treated with vehicle or PDE5I (mirodenafil, 10 mg/kg) for 4 weeks. To examine the effect on erectile response, 6 rats in each group underwent cavernosometry under cavernous nerve electrostimulation (2 V, 0.2 msec, 50 sec, 2.5~20 Hz). The penile tissues from the remaining 6 rats were used for immunohistochemical evaluation of apoptosis. RESULTS: The diabetic group showed markedly lower mean intracavernosal pressure/mean arterial pressure (ICP/MAP) and area under the curve of cavernosometry than normal controls, whereas the diabetes with PDE5I treatment group showed normal results. Despite persistent hyperglycemia, PDE5I treatment significantly reduced the mean apoptotic index (39.6+/-4.6 vs 21.8+/-5.1, p<0.05). CONCLUSIONS: Chronic administration of PDE5I suppressed apoptosis of corporal smooth muscle and improved erectile function in a rat model of diabetic erectile dysfunction.
